Academic literature on the topic 'Drugs Testing Moral and ethical aspects'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drugs Testing Moral and ethical aspects.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Drugs Testing Moral and ethical aspects"
1
Epanomeritakis, Ilias Ektor. "Moral ambivalence towards the Cancer Drugs Fund." Journal of Medical Ethics 45, no. 9 (July 16, 2019): 623–26. http://dx.doi.org/10.1136/medethics-2019-105416.
Full textAbstract:
The UK’s Cancer Drugs Fund (CDF) was introduced in 2010 following the Conservative Party’s promise to address the fact that numerous efficacious cancer drugs were not available because of their cost ineffectiveness, as deduced by the National Institute of Health and Care Excellence. While, at face value, this policy appears only to promote the UK’s public welfare, a deeper analysis reveals the ethically unjustifiable inconsistencies that the CDF introduces; where is the analogous fund for other equally severe diseases? Have the patients without cancer been neglected simply due to the fear-inducing advertising and particularly ferocious speech which surrounds cancer? The CDF is unjustifiable when challenged by such questions. However, it is troubling to think that the CDF might be repealed in order to abolish these ethical concerns. Intuitively, one feels uncomfortable stripping the cancer patient of their benefits just so that they might be on an equally pessimistic footing with others. In the present essay, I argue that, although there are no ethically justifiable grounds for the CDF’s introduction, its removal would be inappropriate. Following this realisation, I investigate whether the procedural steps of the CDF itself—theoretically removed from the context of resource distribution for all disease types—represent an ethically justifiable system. I believe that the answer is yes, given the CDF’s conformity to accountability for reasonableness, a robust framework of procedural justice, which continuously improves the ethical and epistemological standards of the policies to which it is applied.
2
Krajnovic, Dusanka. "Ethical and social aspects on rare diseases." Filozofija i drustvo 23, no. 4 (2012): 32–48. http://dx.doi.org/10.2298/fid1204032k.
Full textAbstract:
Rare diseases are a heterogenic group of disorders with a little in common except of their rarity affecting by less than 5 : 10.000 people. In the world is registered about 6000-8000 rare diseases with 6-8% suffering population only in the European Union. In spite of rarity, they represent an important medical and social problem due to their incidence. For many rare diseases have no treatment, but if it exists and if started on time as being available to patients, there is a good prognosis for them to be able for normal life. The problems of patients affected by rare diseases are related to the lack of diagnosis and timely undergoing as well as their treatment or prevention. Orphan drugs are products intended for treatment, diagnosis or prevention of rare diseases, but for their development and marketing the industry has not been interested in yet because of their marketing reasons. Patients suffering from a rare disease although belonging to the vulnerable group for their specific health needs, is becoming invisible in the health care system due to their additional needs un properly recognized. Ethical problems faced by patients, but also health care professionals are related to the allocation of medical diagnostics, unequal approach to health care, inappropriately specialized social services as well as therapy and rare orphan drugs unavailability. Ethical questions related to clinical trails on orphan drugs, population screening and epidemiology testing on rare diseases will also be discussed in this paper.
3
Surbone, Antonella. "The ethical challenge of genetic testing for breast cancer." Medicina e Morale 48, no. 3 (June 30, 1999): 469–84. http://dx.doi.org/10.4081/mem.1999.799.
Full textAbstract:
The scientific importance of our recently acquired ability to test for heredity predisposition to breast and ovarian cancers is paralleled only by its social and ethical relevance. Dilemmas are common in all genetic testing, but they assume particular nuances in the setting of breast cancer. Due to its devastating nature and to its increasing incidence, breast cancer is a central issue in women’s health. Breast cancer patients and women in general are often deeply involved in understanding the disease process and the treatment options, as they are in discussing the psychological, social and moral ramifications. This paper is a reflection upon some qualitative aspects of the debate that surrounds genetic testing for breast and ovarian cancer, as they have emerged in my encounters with breast cancer patients prior to their decision to consider genetic testing. The five recurrent themes identified in those conversations may or may not be representative of other practice situations, but they illustrate some fundamental philosophical, ethical and moral questions which exist at the core of our human essence and of our moral agency, and which point to the unavoidable intertwinement of medicine, culture, normativity and philosophy, vis-à-vis the many questions raised by genetics. The Author has intentionally refrained from questionnaires, which could betray the complexity of our thinking process, and from the vignettes, as they could betray confidentiality. The paper concludes that the correct answers to the dilemmas posed by genetic testing for breast cancer predisposition can only arise from a blend of medical, social and philosophical analysis.
4
Perry, Joshua E., Ilene N. Moore, Bruce Barry, Ellen Wright Clayton, and Amanda R. Carrico. "The Ethical Health Lawyer: An Empirical Assessment of Moral Decision Making." Journal of Law, Medicine & Ethics 37, no. 3 (2009): 461–75. http://dx.doi.org/10.1111/j.1748-720x.2009.00407.x.
Full textAbstract:
The empirical literature exploring lawyers and their moral decision making is limited despite the “crisis” of unethical and unprofessional behavior in the bar that has been well documented for over a decade. In particular we are unaware of any empirical studies that investigate the moral landscape of the health lawyer’s practice. In an effort to address this gap in the literature, an interdisciplinary team of researchers at Vanderbilt University designed an empirical study to gather preliminary evidence regarding the moral reasoning of health care attorneys. The primary research question was how health lawyers respond when they encounter ethical or moral dilemmas in their practice for which the law fails to offer a bright-line solution. In exploring this question, we sought to understand better what motivations or influences guide action when health lawyers confront ethical quandaries, and whether there are specific differences, e.g., gender, experience, or religiosity, that are associated with specific responses to situations testing ethical or moral boundaries.
5
Mor, Pnina, and Kathleen Oberle. "Ethical Issues Related To BRCA Gene Testing in Orthodox Jewish Women." Nursing Ethics 15, no. 4 (July 2008): 512–22. http://dx.doi.org/10.1177/09697330080150041201.
Full textAbstract:
Persons exhibiting mutations in two tumor suppressor genes, BRCA1 and BRCA2, have a greatly increased risk of developing breast and/or ovarian cancer. The incidence of BRCA gene mutation is very high in Ashkenazi Jewish women of European descent, and many issues can arise, particularly for observant Orthodox women, because of their genetic status. Their obligations under the Jewish code of ethics, referred to as Jewish law, with respect to the acceptability of various risk-reducing strategies, may be poorly understood. In this article the moral direction that Jewish law gives to women regarding testing, confidentiality, and other issues is explored. The intent is to broaden nurses' knowledge of how a particular religious tradition could impact on decision making around genetics testing, with the aim of enhancing their understanding of culturally sensitive ethical care.
6
de Snoo-Trimp, Janine C., Bert Molewijk, Gøril Ursin, Berit Støre Brinchmann, Guy AM Widdershoven, Henrica CW de Vet, and Mia Svantesson. "Field-testing the Euro-MCD Instrument: Experienced outcomes of moral case deliberation." Nursing Ethics 27, no. 2 (June 9, 2019): 390–406. http://dx.doi.org/10.1177/0969733019849454.
Full textAbstract:
Background: Moral case deliberation is a form of clinical ethics support to help healthcare professionals in dealing with ethically difficult situations. There is a lack of evidence about what outcomes healthcare professionals experience in daily practice after moral case deliberations. The Euro-MCD Instrument was developed to measure outcomes, based on the literature, a Delphi panel, and content validity testing. To examine relevance of items and adequateness of domains, a field study is needed. Aim: To describe experienced outcomes after participating in a series of moral case deliberations, both during sessions and in daily practice, and to explore correlations between items to further validate the Euro-MCD Instrument. Methods: In Sweden, the Netherlands, and Norway, healthcare institutions that planned a series of moral case deliberations were invited. Closed responses were quantitatively analyzed. The factor structure of the instrument was tested using exploratory factor analyses. Ethical considerations: The study was approved in Sweden by a review board. In Norway and the Netherlands, data services and review boards were informed about the study. Results: The Euro-MCD Instrument was completed by 443 and 247 healthcare professionals after four and eight moral case deliberations, respectively. They experienced especially outcomes related to a better collaboration with co-workers and outcomes about individual moral reflexivity and attitude, both during sessions and in daily practice. Outcomes were experienced to a higher extent during sessions than in daily practice. The factor structure revealed four domains of outcomes, which did not confirm the six Euro-MCD domains. Conclusion: Field-testing the Euro-MCD Instrument showed the most frequently experienced outcomes and which outcomes correlated with each other. When revising the instrument, domains should be reconsidered, combined with theory about underlying concepts. In the future, a feasible and valid instrument will be presented to get insight into how moral case deliberation supports and improves healthcare.
7
Numminen, Olivia, Jouko Katajisto, and Helena Leino-Kilpi. "Development and validation of Nurses’ Moral Courage Scale." Nursing Ethics 26, no. 7-8 (September 5, 2018): 2438–55. http://dx.doi.org/10.1177/0969733018791325.
Full textAbstract:
Background: Moral courage is required at all levels of nursing. However, there is a need for development of instruments to measure nurses’ moral courage. Objectives: The objective of this study is to develop a scale to measure nurses’ self-assessed moral courage, to evaluate the scale’s psychometric properties, and to briefly describe the current level of nurses’ self-assessed moral courage and associated socio-demographic factors. Research design: In this methodological study, non-experimental, cross-sectional exploratory design was applied. The data were collected using Nurses’ Moral Courage Scale and analysed statistically. Participants and research context: The data were collected from a convenience sample of 482 nurses from four different clinical fields in a major university hospital in Finland for the final testing of the scale. The pilot comprised a convenience sample of 129 nurses. Ethical considerations: The study followed good scientific inquiry guidelines. Ethical approval was obtained from the university ethics committee and permission to conduct the study from the participating hospital. Findings: Psychometric evaluation showed that the 4-sub-scale, 21-item Nurses’ Moral Courage Scale demonstrates good reliability and validity at its current state of development showing a good level of internal consistency for a new scale, the internal consistency values ranging from 0.73 to 0.82 for sub-scales and 0.93 for the total scale, thus well exceeding the recommended Cronbach’s alpha value of >0.7. Principal component analysis and confirmatory factor analysis supported the theoretical construct of Nurses’ Moral Courage Scale. Face validity and expert panel assessments markedly contributed to the relevance of items in establishing content validity. Discussion and conclusion: Nurses’ Moral Courage Scale provides a new generic instrument intended for measuring nurses’ self-assessed moral courage. Recognizing the importance of moral courage as a part of nurses’ moral competence and its assessment offers possibilities to develop interventions and educational programs for enhancement of moral courage. Research should focus on further validation measures of Nurses’ Moral Courage Scale in international contexts.
8
Post, Stephen G. "Dementia in Our Midst: The Moral Community." Cambridge Quarterly of Healthcare Ethics 4, no. 2 (1995): 142–47. http://dx.doi.org/10.1017/s0963180100005818.
Full textAbstract:
This article focuses on the elderly patient with a progressive and irreversible dementia, most often of the Alzheimer type. However dementia, the decline in mental function from a previous state, can occur in all ages. For example, if Alzheimer's disease (AD) is the dementia of the elderly, increasingly AIDS is the dementia of many who are relatively young. I will not present the major ethical issues relating to dementia care following the progression of disease from the mild to the severe stages, for I have done this elsewhere. Among the issues included are: presymptomatic testing, both psychological and genetic; responsible diag- nostic disclosure and use of support groups; restrictions on driving and other activities; preemptive assisted suicide; advance directives for research and treatment; quality of life in relation to the use of life-extending technologies; and euthanasia.
9
ISERSON, KENNETH V. "SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward." Cambridge Quarterly of Healthcare Ethics 30, no. 1 (June 5, 2020): 59–68. http://dx.doi.org/10.1017/s096318012000047x.
Full textAbstract:
AbstractThe world awaits a SARS-CoV-2 virus (i.e., COVID-19 disease) vaccine to keep the populace healthy, fully reopen their economies, and return their social and healthcare systems to “normal.” Vaccine safety and efficacy requires meticulous testing and oversight; this paper describes how despite grandiose public statements, the current vaccine development, testing, and production methods may prove to be ethically dubious, medically dangerous, and socially volatile. The basic moral concern is the potential danger to the health of human test subjects and, eventually, many vaccine recipients. This is further complicated by economic and political pressures to reduce government oversight on rushed vaccine testing and production, nationalistic distribution goals, and failure to plan for the widespread immunization needed to produce global herd immunity. As this paper asserts, the public must be better informed to assess promises about the novel vaccines being produced and to tolerate delays and uncertainty.
10
Lapaeva, Valentina V. "Preimplantation and prenatal genetic diagnostics in Russian Federation: ethical and legal issues." RUDN Journal of Law 25, no. 1 (December 15, 2021): 179–97. http://dx.doi.org/10.22363/2313-2337-2021-25-1-179-197.
Full textAbstract:
The topicality of the article is due to the strategy of transition to personalized medicine in Russia, based, among other things, on technologies of preimplantation and prenatal genetic diagnostics. The purpose of the article is to analyze the main directions of ethical and legal support for the development of these technologies. The work is based on the study of relevant international regulations, foreign and Russian legislation using the methods of legal-dogmatic and philosophical-legal analysis. The article substantiates the need for a clearer distinction between legal and moral-religious approaches to regulating relations in applying these technologies. The task is to find legal structures that can take into account the moral aspects of the problem without replacing legal regulation with an appeal to moral and religious values and norms. An example of this approach is the development of a legal regime for manipulations with embryo in vitro, in which the necessary legal protection of the embryo is provided by recognizing its special ontological status as a constitutional value of the common good. From these positions, the author identifies a range of issues that should form the organizational and legal context necessary to ensure adequate guarantees of human rights in the field of application of the considered genetic technologies. The legal regulation of this range of issues should be fixed in a special federal law on genetic testing.
Dissertations / Theses on the topic "Drugs Testing Moral and ethical aspects"
1
de, Andrade Marisa. "Pharmaffiliation : a model of intra-elite communication in pharmaceutical regulation." Thesis, University of Stirling, 2011. http://hdl.handle.net/1893/6500.
Full textAbstract:
In 2005, the House of Commons (HoC) Health Committee produced a report on The Influence of the Pharmaceutical Industry – the first of its kind since 1914. The inquiry concluded that there were ‘over-riding concerns about the volume, extent and intensity of the industry’s influence, not only on clinical medicine and research but also on patients, regulators, the media, civil servants and politicians’, and stressed the need ‘to examine critically the industry’s impact on health to guard against excessive and damaging dependencies’ (HoC 2005, p. 97). It also noted that it is important to comprehensively analyse pharmaceutical regulation in order to ascertain whether there are systemic problems: In some circumstances, one particular item of influence may be of relatively little importance. Only when it is viewed as part of a larger package of influences is the true effect of the company’s activity recognised and the potential for distortion seen. The possibility that certain components of any such campaign are covert and their source undeclared is particularly worrying. (HoC 2005, p. 97) This study addresses this recommendation and was primarily conducted to examine whether recognised concerns are merely ad hoc or as a result of systemic flaws in the current system of pharmaceutical regulation. The work addresses a gap in the academic literature by drawing on the fragmented criticisms of the pharmaceutical industry in order to produce a model to illustrate how various stakeholders collaborate with drug companies to promote licensed products, and to explore the nature of the relationships between these elite stakeholders. The thesis begins with a literature review which determines who is involved in pharmaceutical regulation; how the regulatory system works; and explores the key role of communication in this process (Chapters 1 to 3). The recurrent theme is the neglect or exclusion of the patient/consumer, which leads to the development a model of intra-elite communication in drug regulation called Pharmaffiliation (Chapter 3). The thesis then looks for evidence to support or refute this model, using multiple methods (Chapter 4). Four case studies (with specific selection criteria) are chosen to test the model’s constructs and indicators (Chapters 5 to 8). The research uncovers systemic problems in the current system of pharmaceutical regulation which can ultimately harm the patient/consumer, and the implications of these findings are discussed (Chapter 9). Solutions on a micro-level include consumer involvement in decision making processes, which can be enhanced through public education and awareness campaigns and the instigation of public inquiries whenever drugs are withdrawn from the market (HoC 2005, p. 105). On a macro-level, however, this will involve critically exploring neoliberal capitalism and the empowerment of the citizenry (Street 2001).
2
Boltman, Tamarah. "Consumers’ perception of generic drugs in South Africa." Thesis, Nelson Mandela Metropolitan University, 2017. http://hdl.handle.net/10948/14664.
Full textAbstract:
Medicines play a pivotal role in the process of human development as their rational utilization can decrease morbidity and mortality as well as improve quality of life (Jamshed, Hassali, Ibrahim, Shafie, & Babar, 2010). Access to therapeutic drugs form an integral part of any successful healthcare system. The high cost of medicines, is a barrier to accessibility and improved health to the majority of the South African population (Bangalee, 2015). In developing countries with limited healthcare budgets, such as South Africa, generic drugs (medicines) can be a cost-saving treatment alternative, resulting in medical expenditure being reduced and access to scarce resources increased (Van der Westhuizen, Burger, Lubbe, Serfontein, 2010). There is very little knowledge on perception and attitude of South African citizens with regard to use of generic drugs (Bangalee, 2015). Consumer perception can have a large impact on the choice of medicines or drugs chosen. The study intended to find out what the current consumer beliefs, attitudes, behaviours and knowledge of generic drugs are. There was also intent to establish if lack of awareness or misconception about generic drugs influence consumer choice. The study consists of a literature review of the definition of generic drugs and original or branded drugs, their influence in the public and private health sector, factors that influence consumer behaviour, brand effect, brand trust, brand loyalty, and most importantly the South Africa acceptance of generic drugs. Primary data was collected, reported and analysed through the use of a questionnaire to determine the current consumers’ belief, attitude, behaviour and knowledge of generic drugs. The study results reveal that scepticism does exists, yet there was clear acceptance, but still lack of confidence in generic drugs. Consumer education and information is the key to increased generic drug acceptance.
3
Knoesen, Brent Claud. "Influence of pharmaceutical advertising on consumers: an exploratory descriptive study." Thesis, Nelson Mandela Metropolitan University, 2007. http://hdl.handle.net/10948/658.
Full textAbstract:
Pharmaceutical advertising involves the advertising of medicines, medical devices, and healthcare services. A review of available international literature indicates the belief that pharmaceutical advertisements negatively affect healthcare decisions made by consumers. Very little research has been conducted to determine how consumers in South Africa (SA) are affected by pharmaceutical advertisements. This study aimed to determine how consumers in the Nelson Mandela Metropole (NMM) perceive pharmaceutical advertisements. More specific objectives included the investigation of legislation in SA employed in pharmaceutical advertisements, the interpretation and misinterpretation of the advertisements, and the identification of problematic areas in this form of advertising. South African legislation applied to pharmaceutical advertisements was investigated by means of a literature review. A qualitative research design was also used to achieve the aim and objectives. This included a focus group consisting of six randomly selected participants in the NMM. A consumer survey, consisting of a 100 consumers obtained from 10 randomly selected community pharmacies within the NMM, supported the findings of the qualitative techniques. The themes identified in the focus group were incorporated into a questionnaire used in the consumer survey. Three randomly selected pharmaceutical advertisements were also decoded to interpret the components employed in each. The results determined that pharmaceutical advertising is a marketing tool that incorporates various emotional and psychological techniques to persuade consumers. It was also evident that consumers can misinterpret pharmaceutical advertisements. Various legal and ethical problems were identified in pharmaceutical advertisements. These results showed that pharmaceutical advertisements have the possibility of negatively affecting consumers’ healthcare decisions and warrants further investigation.
4
Sutton, Erica J. "Prenatal testing and informed choice : the need for improved communication and understanding between health care professionals and pregnant women." Thesis, McGill University, 2003. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=19653.
Full textAbstract:
This research examines the many different ethical issues that emerge in the health care setting with regards to prenatal diagnostic testing. Identifying the areas of clinical practice and religious counselling in need of improvements, particularly physician-client communication, is important to ensure that competent pregnant women make informed, considered choices about prenatal testing. This paper investigates the many factors that contribute to pregnant women's decision-making processes surrounding the acceptance or refusal of the maternal serum alpha-fetoprotein screen, ultrasonography, amniocentesis, chorionic villus sampling, and preimplantation diagnosis. Integrating scholarship in bioethics, religious studies, and the anthropological and sociological study of medicine, this dissertation offers a comparative analysis of religious attitudes toward prenatal diagnostic testing, describes the complexities of practical decision-making by pregnant women faced with genuine ethical dilemmas, and provides an analysis of ethical issues related to prenatal testing. This research will be of interest to scholars in religious studies and bioethics, prenatal genetic counsellors and obstetricians involved in the provision of prenatal diagnostic testing services, and specialists in women's health and reproductive decisionmaking.
5
Loff, Beatrice. "Health and human rights : case studies in the potential contribution of a human rights framework to the analysis of health questions." Monash University, Dept. of Epidemiology and Preventive Medicine, 2004. http://arrow.monash.edu.au/hdl/1959.1/5291.
Full text
6
Bellmore, Aimée Ryan. "Gender, Culture, and Prison Classification: Testing the Reliability and Validity of a Prison Classification System." PDXScholar, 2011. https://pdxscholar.library.pdx.edu/open_access_etds/423.
Full textAbstract:
Research consistently shows actuarial classification instruments have equal or higher predictive validity than clinical judgment and can lead to more ethical and fair treatment of incarcerated men and women (Austin, 1983, 1986; Bonta, 2002; Clements, 1981; Holsigner, Lowenkamp, & Latessa, 2006; Meehl, 1954; Salisbury, Van Voorhis, & Spiropoulos, 2009). Best correctional practice recommends all objective classification systems are tested for reliability and validity to ensure they are effective for the population they intend to serve (Austin, 1986; Holsinger et al., 2006; Salisbury et al., 2009). This study examined the reliability and validity of the classification and assessment instruments currently used by Golden Grove Adult Correctional Facility (Golden Grove), located on St. Croix in the United States Virgin Islands (USVI). Golden Grove is a mixed-gender, mixed-security status prison managed by the USVI territorial government, and is subject to United States Federal laws and mandates. Data from archival files were used to assess the internal reliability, construct validity, and predictive validity of the classification and assessment instruments used with incarcerated men and women at Golden Grove (N = 200). Primary objectives of this study were separated into four main categories: 1) examine the construct validity of Golden Grove's custody assessment tools; 2) investigate the predictive validity of Golden Grove's custody assessment tools across gender; 3) determine reliability and assess to what extent the primary classification officer's decisions have higher predictive validity than the actuarial tool; and 4) investigate the relationship between items on the needs assessment form and level of custody (minimum, medium, or maximum). Results were mixed but generally indicated weak reliability, construct validity, and predictive validity. Contrary to most research on gender and classification, a significant correlation between the initial custody score for incarcerated females and disciplinary reports (r = .26, n = 56, p < .05) indicated the initial custody tool predicted misconduct for maximum custody females better than for males. The mean number of disciplinary reports for maximum women (M = 1.12) was significantly higher compared to maximum men (M = .46). The classification officer overrode the instrument at a high rate for both the initial assessment instrument (44%) and the reassessment instrument (36.4%) rendering the objective assessment overly subjective. Overall, findings show the classification system at Golden Grove is not functioning as intended and improvements are recommended.
7
McDermott, Vanessa. "Conceptualising legitimacy, moral panics and performance enhancing drugs : Crisis? Whose crisis?" Phd thesis, 2011. http://hdl.handle.net/1885/150782.
Full textAbstract:
In the debate surrounding performance enhancing drugs (PEDs) in sport, academic investigation has focused mainly on why some individual athletes use PEDs while other actors refrain from doing so. In this thesis I adopt a broader social perspective and argue that the debate can be usefully reframed by considering how sports governing bodies (SGBs) maintain legitimacy and moral authority over their sporting communities. This highlights how various drug-related controversies and reports are associated with a crisis of legitimacy for SGBs.
The thesis adopts a social constructionist perspective, using a modified'moral panic' framework based on the work of Goode and Ben-Yehuda. Situating legitimacy within this moral panic model reveals the'multifaceted' nature of legitimacy and the way doping debate reflects the interests of elite SGBs. At the same time, elite SGBs affected by the debate can use the media to resist other elite SGBs and impose their own interpretation of reality upon the situation. Using a grounded theoretical model, I examine whether the anti-doping debate is an example of a 'moral panic,' involving PED-using 'folk devils.'
In the first part of this thesis I present a socio-historical examination of anti-doping policies and interactions between the International Olympic Committee (IOC), the World Anti-Doping Agency (WADA) and the Australian Football League (AFL). Multiple methods were used, including a review of media coverage, an online survey and follow-up interview with sporting participants. This multi-layered approach revealed how the creation of PED-using 'folk devils' challenges SGBs legitimacy, while also providing opportunities to restore perceptions of legitimacy. A quantitative e-Survey and follow-up interviews revealed that grassroots sporting participants in Australia accepted there was a crisis of legitimacy for SGBs, even if the perceived causes of this crisis varied. Using this multi-dimensional approach, I conclude that the debate surrounding PEDs provides an example of a moral panic engineered by elite SGBs, and particularly WADA, based on a concern with maintaining the moral authority and legitimacy to control the ever-widening global sporting community.
8
"Underwriting guidelines for genetic testing with special reference to the relevant ethical aspects." Thesis, 2012. http://hdl.handle.net/10210/5701.
Full textAbstract:
M.Comm.A revolution in genetic research, known as the Human Genome Project (HGP), is taking place. This project, initiated in 1984, is a twenty-year, six billion-dollar science project designed to map the entire genetic structure (Genome) of the human species (Brockett and Tankersley, 1995). In 1998, the HGP leaders expected to complete the project by 2003 (Lowden, J. A., 1999:33). The Human Genome Project is designed to sequence the human genome (the blue print of genetic information) and to identify the estimated 100000 genesherein. This has added a new dimension to the technology available to underwriters in the life and health insurance industry for the selection of medical risks. Genetic testing can identify inherited diseases and predict illnesses that might not manifest for decades (Brackenridge & Elder, 1998:89). Genome research has opened up new opportunities for diagnosis and in some cases, early treatment of medical conditions. This new basis of knowledge is referred to as the advent of the molecular age in medicine. Medical journals, the mass media and genetic interest groups are treating human genetics and the opportunities it presents as a high-profile issue, with great attention being paid to the complex and emotive topics of life insurance and genetic testing (Regenauer & Schmidtke, 1998:5). The Insurance Industry can use genetic testing to identify high-risk applicants more accurately and price products accordingly, thereby improving risk assessment and profitability. These potential advantages, however, are counter-balanced by ethical considerations that are much more difficult to address (Lowden, J. A., 1999:33). Many consumers, ethicists and geneticists fear that insurers will use this data for unfair discriminatory purposes, identifying a genetic underclass of people who, although clinically well, will be uninsurable. Genetic testing could invade the privacy of applicants and their families. There are concerns about the confidential handling of genetic information as well as the accurate interpretation of genetic tests. The uncertainty about the predictive value of genetic tests, the shortage of trained geneticists and counsellors and the psychological impact of that knowledge of a predictable serious disease might have, have lead to much opposition to the use of genetic information by third parties. In the United States most Americans receive health insurance through their place of employment. There are fears that genetic testing will be used to discriminate against prospective employees and render many people unemployable and uninsurable (Council for responsible Genetics, 1997: http://www.gene-watch.org/genclisc htuil Consumer groups have lobbied effectively for the prohibition of testing or the use of testing by insurers in the United States and Europe and legislators aim to ban the use of genetic information on a broad basis. Insurers, on the other hand, are assuming that the new laws will cause untold damage to the fiscal stability of their companies (Lowden, J. A., 1999:33). However, it seems inevitable that genetic testing will affect risk classification sooner rather than later and to a greater extent than most believe (Chambers, 1997: http://www.Inrc.com/epirr/issues/143/143-4.htm).
9
Coetzee, Anje. "A multiple stakeholder perspective on ethics challenges in online testing." Thesis, 2015. http://hdl.handle.net/10210/14381.
Full textAbstract:
M.A.With the more popular practice of communication through emails, cellular phones, and instant online messaging, the pace at which organisations communicate and function has increased dramatically over the past decade, as information is speedily available. Organisations need to adapt to the latest technology applications in order to be more efficient and to increase productivity ...
10
Park, Gerald H. "Content of an ethics course for nondestructive testing and welding inspection personnel." Thesis, 1993. http://hdl.handle.net/1957/36501.
Full textAbstract:
This research evaluated the ethics competencies which were
determined to be important to the curriculum of an ethics course for
students studying Nondestructive Testing and Welding Inspection. Data
were gathered from samples of American Society of Nondestructive
Testing Nationally Certified Level III's (N = 268), American Welding
Society Nationally Certified Welding Inspectors CWI's (N = 212) and
American Welding Society Nationally Certified Associate Welding
Inspectors - CAWI's (N = 101) who are currently licensed by their
respective societies.
The twenty-nine (29) item instrument utilized a six-point Likert type
scale for the data collection. The scale, which was validated by
consensus using a DELPHI panel procedure, utilized the Hoyt-Stunkard
method for assessing reliability. The computed reliability for the
instrument was determined to be +0.970.
Analysis of variance tests were completed for each of the twenty-nine
(29) competencies to ascertain differences between ASNT Level
III's, AWS CWI's and AWS CAWI's samples. Factor analysis, using the R-mode,
provided for the clustering of competencies and constituted the
major analysis procedure for the study.
The results of the study indicated the presence of three (3) clusters
of content which were considered necessary to curriculum inclusion in an
ethics course for nondestructive testing and welding inspection. The
identified clusters include: I. Ethical issues and personal integrity (18
competencies), II. Ethics and the legal aspects of inspection (8
competencies), and III. Ethical theory and professional conduct (4
competencies).
Overall competency means ranged from 3.929 to 5.594;
significance tests showed only five (5) rejected hypotheses for the twent-ynine
(29) primary competencies. Standard errors of the mean were
found to be lower for the ASNT Level III's sample.
The results of the study present a valid pattern for the development
of objectives which should be included in an ethics curriculum for
nondestructive testing personnel and welding inspectors.Graduation date: 1993
Books on the topic "Drugs Testing Moral and ethical aspects"
1
Brody, Baruch A. Ethical issues in drug testing, approval, and pricing: Theclot-dissolving drugs. New York: Oxford University Press, 1995.
Find full text
2
Ethical issues in drug testing, approval, and pricing: The clot-dissolving drugs. New York: Oxford University Press, 1995.
Find full text
3
Flamant, Robert. Malade ou cobaye: Plaidoyer pour les essais thérapeutiques. Paris: A. Michel, 1994.
Find full text
4
Access to experimental drugs in terminal illness: Ethical issues. New York: Pharmaceutical Products Press, 1998.
Find full text
5
Ethical and scientific issues in studying the safety of approved drugs. Washington, D.C: National Academies Press, 2012.
Find full text
6
Richard, Aline. Cobayes humains: Les secrets de l'expérimentation médicale. Paris: La Découverte, 1988.
Find full text
7
United States. National Bioethics Advisory Commission. Ethical and policy issues in international research: Clinical trials in developing countries. Bethesda, Md. (6705 Rockledge Dr., Ste. 700, Bethesda 20892-7979): National Bioethics Advisory Commission, 2001.
Find full text
8
Bad pharma: How drug companies mislead doctors and harm patients. New York: Faber and Faber, 2013.
Find full text
9
Medical research for hire: The political economy of pharmaceutical clinical trials. New Brunswick, N.J: Rutgers University Press, 2009.
Find full text
10
O'Meara, Alex. Chasing medical miracles: The promise and perils of clinical trials. New York: Walker & Co., 2009.
Find full text